Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

The Medtronic APOLLO Clinical Trial is evaluating the safety and efficacy of an investigative device called the Intrepid Transcatheter Mitral Valve Replacement System (TMVR) for moderate-to-severe or severe symptomatic mitral regurgitation (MR) in patients who may be unsuitable for approved transcatheter repair or surgery.

News | Structural Heart

Hackensack Meridian Jersey Shore University Medical Center Providing State-of-the-Art Medtronic APOLLO Clinical Trial Treating Heart Valve Disease

February 20, 2024 — As New Jersey’s leading provider of high-quality cardiac procedures and diagnostic testing and an ...

February 20, 2024

The study, titled "Targeted Therapy with Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy" (TaRGET), will be led by the research team at PHRI and will involve collaboration with multiple organizations in addition to AMO Pharma including the Hearts in Rhythm Organization (HiRO).

News | Pharmaceuticals

AMO Pharma Announces Collaboration with Population Health Research Institute to Advance Proof of Concept Clinical Trial to Assess Efficacy of Tideglusib in Treatment of Arrhythmogenic Cardiomyopathy

February 16, 2024 — AMO Pharma Limited, a privately held clinical-stage specialty biopharmaceutical company focusing on ...

February 16, 2024

Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a subsidiary of Bayer AG, have announced that the first patient has been randomized in GenePHIT (Gene PHosphatase Inhibition Therapy), a Phase II trial of AB-1002, also known as NAN-101, for the treatment of congestive heart failure (CHF).

News | Cardiovascular Clinical Studies

First Patient Randomized in AskBio Phase II Gene Therapy Trial for Congestive Heart Failure Treatment

February 15, 2024 — Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and ...

February 15, 2024

The limited clinical trial represents the first human implantation of a cardiac auscultation sensor device

News | Heart Failure

Canary Completes First-in-Human Trial of Cardiac Auscultation Monitoring Sensor

February 15, 2024 — Canary Medical, a medical data company focused on the development and commercialization of its ...

February 15, 2024

Novel bioresorbable scaffold system being developed for expanded indications

News | Stents Bioresorbable

AI Measures Fat Around the Heart, a Key to Predicting Heart Attacks

February 14, 2024 — Efemoral Medical, developer of advanced interventional bioresorbable therapies, today announced that ...

February 14, 2024

The replacement of regular salt with a salt substitute can reduce incidences of hypertension, or high blood pressure, in older adults without increasing their risk of low blood pressure episodes, according to a study published in the Feb. 2024 issue of the Journal of the American College of Cardiology (JACC).

News | Hypertension

DECIDE-Salt Study Finds Salt Substitutes Help to Maintain Healthy Blood Pressure in Older Adults

February 14, 2024 — The replacement of regular salt with a salt substitute can reduce incidences of hypertension, or ...

February 14, 2024

In a groundbreaking study, researchers from The Texas Heart Institute, Baylor College of Medicine, Texas Children's Hospital, and the University of Texas Health Science Center McGovern Medical School have shed light on the underlying molecular cell states within transplanted pediatric hearts, paving the way for improved treatment strategies and enhancing the longevity of cardiac allografts.

News | Pediatric Cardiology

Revolutionary Genomic Study Sheds Light on Immune Microenvironment in Transplanted Pediatric Hearts

February 13, 2024 — Pediatric heart transplantation has long been hailed as a life-saving intervention for children ...

February 13, 2024

The company’s roster of clinical evidence continues to grow, with data highlights on expediting, broadening, and challenging current guidelines in stroke care

News | Stroke

RapidAI Announces Late-Breaking Abstract Simultaneously Published in NEJM; Highlights Key Data Revealed at ISC 2024

February 13, 2024 — RapidAI, the global leader in developing Artificial Intelligence (AI) and clinical workflow ...

February 13, 2024

Cleerly has announced continued strong scientific evidence supporting the clinical utility of its products, detailing a study published online on Jan. 25, 2024 in the European Heart Journal Cardiovascular Imaging

News | Artificial Intelligence

Results of CERTAIN Study Demonstrate Prominent Effects of Cleerly Products on Changing Clinical Management for Patients Suspected of Coronary Artery Disease

February 13, 2024 — Cleerly, a digital healthcare company focused on artificial intelligence (AI)-driven heart disease ...

February 13, 2024

Millions of patients worldwide could benefit from better long-term outcomes by the company’s expansion into peripheral artery disease

News | Peripheral Artery Disease (PAD)

Sensome Announces Initiation of Clinical Trial Assessing Its Tissue Microsensor Technology in Peripheral Artery Disease

February 12, 2024 — Sensome, a company pioneering the connected medical device revolution with the world’s smallest ...

February 12, 2024

Results show statistically significant decreases in stroke volume, edema, and necrotic area versus controls

News | Stroke

VST BIO Announces Groundbreaking Data from Non-Human Primate Study Evaluating Novel Monoclonal Antibody to Treat Ischemic Stroke at AHA International Stroke Conference

February 12, 2024 — VST Bio Corp. a leader in the development of innovative biologics to treat acute and chronic cardiov ...

February 12, 2024

A team at Allina Health Minneapolis Heart Institute at Abbott Northwestern Hospital has successfully completed the first Barostim Baroreflex Activation Therapy implant in the state of Minnesota, according to an announcement from CVRx, Inc. and Allina Health.

News | Heart Failure

Allina Health Minneapolis Heart Institute is First in Minnesota to Implant Barostim Therapy to Improve Symptoms of Heart Failure

February 12, 2023 — A team at Allina Health Minneapolis Heart Institute at Abbott Northwestern Hospital has successfully ...

February 12, 2024

Primary effectiveness endpoint results show high revascularization rates of 93.9% mTICI 2b/3

News | Stroke

MIVI Neuroscience Presents Primary Endpoint Results from the EvaQ Trial — at the 2024 International Stroke Conference

February 9, 2024 — MIVI Neuroscience, Inc. announced the primary endpoint results of its EvaQ Trial, a prospective ...

February 09, 2024

Physicians in the Smidt Heart Institute at Cedars-Sinai have pioneered using a catheter-based approach to treat patients with tricuspid valve disease. Image by Getty.

News | Structural Heart

Smidt Heart Institute Physicians Advance Transcatheter Tricuspid Valve Replacement

February 9, 2024 — Physicians in the Smidt Heart Institute at Cedars-Sinai have achieved two significant firsts ...

February 09, 2024

ResearcherLate-breaking science from the American Stroke Association’s International Stroke Conference, ISC 2024, reports researchers found an artificial intelligence (AI) system to help guide treatment decisions for stroke patients led to improved stroke care quality and fewer recurrent strokes, heart attacks and vascular death among stroke survivors three months after a stroke.

News | AHA

International Stroke Conference Researcher Finds AI-based System Helped Guide Treatment, Lowered Stroke Recurrence

February 8, 2024 — The latest late-breaking science from the second day of the American Stroke Association’s Internation ...

February 08, 2024